Cellectar Biosciences Inc (CLRB) - News Archive

: Pancreatic cancer (PC) presents one of the most formidable challenges in oncology, characterized by late-stage diagnosis, rapid progression, and limited treatment options. Recent advances in radiopharmaceuticals have...

In a significant advancement in cancer treatment, Cellectar Biosciences Inc. has entered a supply agreement with ITM Isotopen Technologien München AG, paving the way for the clinical development of CLR 121225, an innova...

: Cellectar Biosciences is making notable strides in the treatment of pancreatic cancer with its promising novel drug CLR 121225, showcased at the American Association for Cancer Research (AACR) Special Conference. This...

Cellectar Biosciences, a prominent player in the pharmaceutical research and development sector, recently provided a strategic update highlighting significant progress within its clinical pipeline, current market perfor...

: The pharmaceutical landscape continuously evolves through collaborations and technological advancements. A recent partnership between NorthStar Medical Radioisotopes and Cellectar Biosciences highlights the potential...

Cellectar Biosciences Inc. (NASDAQ: CLRB) finds itself at a critical juncture as various news reports illuminate a complex landscape of opportunities and challenges. Recent developments surrounding its lead therapy cand...

Cellectar Biosciences Announces Successful Exercise of Tranche B Warrants and Potential for Additional Funding of up to $73.3 MillionFLORHAM PARK, N.J., July 22, 2024 - Cellectar Biosciences, a prominent late-stage clin...

In a recent press release, Cellectar Biosciences, a renowned biopharmaceutical company, announced positive findings from an investigator-initiated Phase 1 study evaluating the safety and efficacy of Iopofosine in combin...

Cellectar Biosciences has begun enlisting participants for its Phase 1b clinical study focusing on pediatric high-grade gliomas, a significant milestone in oncological research. The U.S. clinical-stage biopharmaceutical...

FLORHAM PARK, N.J., Jan. 25, 2024 - Cellectar Biosciences, Inc. (NASDAQ: CLRB), a renowned late-stage clinical biopharmaceutical company specializing in the research, development, and commercialization of innovative can...

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical DataIn a recent press release, Cellectar Biosciences, a clinical-stage biopharmaceutical comp...

Cellectar Biosciences, a leading clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of innovatively prepared drugs for cancer treatment, has declared their alliance wi...

Promising Results: Cellectar Biosciences Iopofosine I 131 Demonstrates Success as a Groundbreaking Radiotherapy Candidate for Waldenstroms MacroglobulinemiaIn a groundbreaking development, Cellectar Biosciences, a leadi...

In a bold stride toward combating pediatric cancer, Cellectar Biosciences have revealed their plans to expand the collaboration with the Wisconsin Alumni Research Foundation (WARF) in an exclusive licensing agreement me...